EP1157275A4 - Novel transduction molecules and methods for using same - Google Patents

Novel transduction molecules and methods for using same

Info

Publication number
EP1157275A4
EP1157275A4 EP00962058A EP00962058A EP1157275A4 EP 1157275 A4 EP1157275 A4 EP 1157275A4 EP 00962058 A EP00962058 A EP 00962058A EP 00962058 A EP00962058 A EP 00962058A EP 1157275 A4 EP1157275 A4 EP 1157275A4
Authority
EP
European Patent Office
Prior art keywords
methods
same
transduction molecules
novel transduction
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00962058A
Other languages
German (de)
French (fr)
Other versions
EP1157275A1 (en
Inventor
Steven F Dowdy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Washington University in St Louis WUSTL filed Critical University of Washington
Publication of EP1157275A1 publication Critical patent/EP1157275A1/en
Publication of EP1157275A4 publication Critical patent/EP1157275A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
EP00962058A 1999-02-28 2000-02-28 Novel transduction molecules and methods for using same Withdrawn EP1157275A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12275799P 1999-02-28 1999-02-28
US122757P 1999-02-28
US15129199P 1999-08-29 1999-08-29
PCT/US2000/005097 WO2000062067A1 (en) 1999-02-28 2000-02-28 Novel transduction molecules and methods for using same
US151291P 2009-02-10

Publications (2)

Publication Number Publication Date
EP1157275A1 EP1157275A1 (en) 2001-11-28
EP1157275A4 true EP1157275A4 (en) 2003-01-15

Family

ID=26820859

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00962058A Withdrawn EP1157275A4 (en) 1999-02-28 2000-02-28 Novel transduction molecules and methods for using same

Country Status (5)

Country Link
EP (1) EP1157275A4 (en)
JP (1) JP2003514765A (en)
AU (1) AU7497000A (en)
CA (1) CA2364690A1 (en)
WO (1) WO2000062067A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ517663A (en) 1999-08-16 2006-02-24 Revaax Pharmaceuticals Llc Neurotherapeutic clavulanate composition and method
AU7473500A (en) 1999-09-01 2001-03-26 University Of Pittsburgh Identification of peptides that facilitate uptake and cytoplasmic and/or nucleartransport of proteins, dna and viruses
FR2816845B1 (en) * 2000-11-20 2006-10-20 Centre Nat Rech Scient TRANSPORT VECTORS THROUGH A GREEN JUNCTION EPITHELIUM
US20020073441A1 (en) * 2000-12-13 2002-06-13 Ross Brian D. Compositions and methods for detecting proteolytic activity
FR2818982B1 (en) * 2000-12-29 2003-10-31 Univ Rennes SPECIFIC INHIBITOR OF THE UBIQUITINE-PROTEASOME SYSTEM AND CORRESPONDING THERAPEUTIC APPLICATIONS
US20030045679A1 (en) * 2001-07-13 2003-03-06 Crawford Dana R. Calcineurin modulators
FR2829940A1 (en) * 2001-09-27 2003-03-28 Synt Em New composition, useful for treating central nervous system diseases, comprises an antibody linked to a linear peptide and is able to cross the blood-brain barrier
EP1575548B1 (en) 2002-05-04 2011-03-09 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
EP2567705A3 (en) * 2002-06-04 2013-07-03 Avicena Group, Inc. Methods of treating cognitive dysfunction by modulating brain energy metabolism
EP1947116B1 (en) * 2003-02-10 2017-06-21 2-BBB Medicines B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
US7166692B2 (en) 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
JP5399612B2 (en) * 2003-05-16 2014-01-29 アコーダ セラピューティクス、インク． Fusion protein for treating CNS
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
MXPA05012307A (en) 2003-05-16 2006-07-03 Acorda Therapeutics Inc Proteoglycan degrading mutants for treatment of cns.
ES2308200T3 (en) * 2003-06-30 2008-12-01 Universite De Lausanne PEPTIDE DERIVED FROM RASGAP TO SELECTLY DESTROY CANCER CELLS.
CN1648135A (en) * 2004-01-20 2005-08-03 中国人民解放军军事医学科学院毒物药物研究所 Transduction peptide-humanized chloine acetylase fusion protein and its use
AU2005244933B2 (en) 2004-05-18 2011-08-04 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
DK1988167T3 (en) 2005-02-17 2020-07-13 Univ Sorbonne Intracellular inhibitory peptides
DE602006017237D1 (en) 2005-04-05 2010-11-11 Allergan Inc Clostridientoxinaktivitätstests
EP1928490B8 (en) 2005-09-26 2012-10-03 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
JP4677319B2 (en) * 2005-10-05 2011-04-27 東亞合成株式会社 Nerve differentiation inhibitor peptide and use thereof
US8883507B2 (en) 2005-10-18 2014-11-11 The Regents Of The University Of Colorado Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
WO2007115578A1 (en) * 2006-04-07 2007-10-18 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Synthetic mecp2 sequence for protein substitution therapy
US7722864B2 (en) 2006-10-10 2010-05-25 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
AU2008224950B2 (en) 2007-03-13 2013-10-03 National Jewish Medical And Research Center Methods for generation of antibodies
IL287311B1 (en) 2008-05-16 2024-02-01 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
ES2525411T3 (en) 2008-07-21 2014-12-22 Taiga Biotechnologies, Inc. Differentiated anucleated cells and method to prepare them
EP2966084B1 (en) 2008-08-28 2018-04-25 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same and methods of identifying agents that modulate myc
JP5626717B2 (en) * 2009-03-26 2014-11-19 学校法人日本大学 Fusion protein containing retinoic acid receptor α
US8940286B2 (en) * 2009-06-22 2015-01-27 The University Of Tokyo Urate transporter, as well as method and kit for evaluating urate transport-related disease factor and inflammation-related disease factor, and test sample and drug
CA2780741C (en) 2009-10-12 2023-04-04 Smith Holdings, Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
WO2012038950A1 (en) 2010-09-20 2012-03-29 Ramot At Tel-Aviv University Ltd. Activatable toxin complexes comprising a cleavable inhibitory peptide
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CN114645015A (en) 2012-07-20 2022-06-21 泰加生物工艺学公司 Enhanced reconstitution and autoreconstitution of hematopoietic compartments
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
WO2014194259A1 (en) * 2013-05-30 2014-12-04 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Methods and compositions for treating brain diseases
US10583156B2 (en) 2016-12-02 2020-03-10 Taiga Biotechnologies, Inc. Nanoparticle formulations
CN111107870A (en) 2017-06-22 2020-05-05 催化剂生物科学公司 Modified membrane serine protease 1(MTSP-1) polypeptides and methods of use thereof
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
KR20210110848A (en) 2018-12-28 2021-09-09 카탈리스트 바이오사이언시즈, 인코포레이티드 Modified urokinase type plasminogen activator polypeptides and methods of use
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
WO1999029721A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5328984A (en) * 1991-03-04 1994-07-12 The United States As Represented By The Department Of Health & Human Services Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells
WO1998051325A2 (en) * 1997-05-15 1998-11-19 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
WO1999029721A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BONIFACI N ET AL: "NUCLEAR TRANSLOCATION OF AN EXOGENOUS FUSION PROTEIN CONTAINING HIV TAT REQUIRES UNFOLDING", AIDS, LONDON, GB, vol. 9, no. 9, 1995, pages 995 - 1000, XP002913782, ISSN: 0269-9370 *
CHEN L L ET AL: "INCREASED CELLULAR UPTAKE OF THE HUMAN IMMUNODEFICIENCY VIRUS-1 TATPROTEIN AFTER MODIFICATION WITH BIOTIN", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 227, 1995, pages 168 - 169,172-175, XP002917757, ISSN: 0003-2697 *
NAGAHARA H ET AL: "TRANSDUCTION OF FULL-LENGTH TAT FUSION PROTEINS INTO MAMMALIAN CELLS: TAT-P27KIP1 INDUCES CELL MIGRATION", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 4, no. 12, December 1998 (1998-12-01), pages 1449 - 1452, XP002927987, ISSN: 1078-8956 *
PHELAN A ET AL: "INTERCELLULAR DELIVERY OF FUNCTIONAL P53 BY THE HERPESVIRUS PROTEIN VP22", NATURE BIOTECHNOLOGY, NATURE PUB. CO, NEW YORK, NY, US, vol. 16, no. 5, May 1998 (1998-05-01), pages 440 - 443, XP000979081, ISSN: 1087-0156 *
SCHWARZE S ET AL: "In vivo protein transduction: delivery of a biologically active protein into the mouse", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 285, no. 5433, 3 September 1999 (1999-09-03), pages 1569 - 1572, XP002140133, ISSN: 0036-8075 *
See also references of WO0062067A1 *

Also Published As

Publication number Publication date
CA2364690A1 (en) 2000-10-19
EP1157275A1 (en) 2001-11-28
WO2000062067A9 (en) 2002-07-11
AU7497000A (en) 2000-11-14
WO2000062067A1 (en) 2000-10-19
JP2003514765A (en) 2003-04-22

Similar Documents

Publication Publication Date Title
EP1157275A4 (en) Novel transduction molecules and methods for using same
EP1552002A4 (en) Aptamer-toxin molecules and methods for using same
AU3662101A (en) Cd40-binding apc-activating molecules
EP1223932A4 (en) Compounds and methods
EP1146790A4 (en) Compounds and methods
AUPQ339899A0 (en) Novel molecules
EP1091240A4 (en) Single-photon-emission apparatus
HUP0103473A3 (en) Phosphoglycolipid and methods for its use
EP1147213A4 (en) Novel rgs-containing molecules and uses thereof
AU9275498A (en) Chiral amines
GB9721961D0 (en) Novel molecules
AU2587399A (en) Human transport-associated molecules
GB9925679D0 (en) Novel process and apparatus
AUPQ583100A0 (en) Fastening apparatus and methods for their production and use
GB0022670D0 (en) Molecules
GB2349010B (en) Variable capo tasto
GB0002625D0 (en) Dendroaspin molecules
GB9906206D0 (en) Fermentation apparatus
AU2664999A (en) Human channel-related molecules
GB9912635D0 (en) Molecules
GB9925490D0 (en) Binding molecules and treatment and screening methods
GB9923117D0 (en) Insect-paper and methods for its formation and use
GB9900419D0 (en) Polarizers
GB9800460D0 (en) Polarizers
GB9904967D0 (en) Musical mixing unit

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010920

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20021203

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7G 01N 33/567 A, 7C 12N 15/00 B, 7C 07K 14/00 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030902